Association of KPC-producing Klebsiella pneumoniae colonization or infection with Candida isolation and selection of non-albicans species

Diagn Microbiol Infect Dis. 2014 Nov;80(3):227-32. doi: 10.1016/j.diagmicrobio.2014.07.012. Epub 2014 Aug 6.

Abstract

Clinical specimens from 565 patients hospitalized in 2 intensive care units (ICUs A and B) during a 28-month period were cultured on appropriate media for isolation of Candida. Forty-nine (9%) patients had at least a Candida spp.-positive sample. Candida albicans was the predominant species isolated from 26 (53%) patients. Seventeen patients (3%) developed candidemia. Multivariate analysis showed that obesity, female gender, hospitalization during summer months, admission at ICU B, parenteral nutrition, administration of metronidazole, transplantation, and KPC-producing Klebsiella pneumoniae (KPC-Kp) infection were independently associated with Candida spp. isolation. Candidemia was associated with cortisone administration, KPC-Kp infection, and presence of colostomy or abdominal catheter. Administration of fluconazole was a protective factor for both Candida spp. isolation and infection, leading to selection of Candida non-albicans species. Among several risk factors, KPC-Kp infection and colonization are identified as statistically significant factors associated with Candida isolation, especially of non-albicans species.

Keywords: Candidemia; Critically ill patients; Intensive care unit.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antifungal Agents / therapeutic use
  • Candida / classification
  • Candida / isolation & purification*
  • Candidiasis / epidemiology*
  • Candidiasis / microbiology
  • Carrier State / microbiology
  • Critical Illness
  • Female
  • Fluconazole / therapeutic use
  • Humans
  • Intensive Care Units
  • Klebsiella Infections / complications*
  • Klebsiella Infections / microbiology
  • Klebsiella pneumoniae / enzymology*
  • Klebsiella pneumoniae / isolation & purification*
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors
  • Treatment Outcome
  • beta-Lactamases / metabolism*

Substances

  • Antifungal Agents
  • Fluconazole
  • beta-Lactamases